BioNTech and partner DualityBio are accelerating the development of their B7-H3 antibody-drug conjugate into a phase 3 trial for metastatic castration-resistant prostate cancer (mCRPC). | BioNTech and ...

FG-3246 and enzalutamide combination therapy, in biomarker unselected patients with androgen receptor pathway inhibitor (ARPI)-treated, ...

Kyntra Bio Inc. KYNB, formerly Fibrogen, shares fluctuated in Tuesday’s premarket session as the company announced data from a Phase 1b/2 study of FG-3246 in combination with enzalutamide for treating ...

(RTTNews) - INmune Bio, Inc. (INMB), a clinical-stage biotechnology company focused on immunotherapy treatments, announced Tuesday the expansion of its ongoing Phase I/II trial to include veterans ...

Scientists have identified two enzymes that help prostate cancer cells grow, survive and resist treatment, paving the way for new and more effective treatments. An international team has uncovered two ...

CDX Prostate is a blood-based diagnostic tool that uses AI-powered learning to determine the risk of aggressive prostate cancer. Florida-based Protean BioDiagnostics will now offer the validated CDX ...

Boca Raton, Florida, April 29, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (INMB) (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the ...

Neuroendocrine prostate cancer (NEPC) is the most aggressive form of prostate cancer, responsible for up to 20% of therapy-resistant cases and associated with rapid disease progression. It is ...

Prostate Screening EpiSwitch (PSE) blood test shows significant potential as an accurate and rapid cancer screening diagnostic High accuracy (94%), PPV (92%), and NPV (94%) reported in the high-impact ...

MINNEAPOLIS, April 15, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) announced today that Exosome Diagnostics, a Bio-Techne brand, is launching an ExoDx™ Prostate Test At-Home Collection ...